This website uses cookies to enhance the user experience.
I

IC TARGETS AS984 531 524

Research
Limited company
c/o Parallell Lørenveien 73A 0585 OSLO, Norge

IC TARGETS AS

IC Targets – Opportunities within the original indication
Norwegian Contrasts Vision Vision Our vision is to become a leading company in providing manganese-based contrast agents. About us IC Targets AS is a life-science company dedicated to the development of manganese-based MRI contrast agents and new methods that will improve diagnostic imaging. The main

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Links

Organization

Chairman of the board
Years since formation
22 years
since May 21, 2002
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
9,751,881
1 share class
Total number of shareholders
54
31 companies, 23 persons

Financials

Total operating income 2023
5,709,789
NOK
Annual total result 2023
5,554,028
NOK
Total equity 2023
3,584,934
NOK
Last update: Aug 29, 2024

Management

Board

NameRoleShares
Contact Person, Chairman
21.32 %
directly < 0.01 %
indirectly 21.32 %
Board Member-
Board Member
7.64 %
directly
Board Member-
Board Member-

Others

NameRoleShares
M
MOORE AS
Auditor-
S
SJØLYST REGNSKAP AS
Accountant-

Top 10 individual shareholders

NameRoleShares
Contact Person, Chairman
21.32 %
directly < 0.01 %
indirectly 21.32 %
Board Member
7.64 %
directly
-
6.15 %
indirectly
PJ
-
5.29 %
directly
-
5.02 %
directly
-
2.3 %
indirectly
-
2.05 %
directly 1.13 %
indirectly 0.92 %
-
1.17 %
directly
Last update: Jul 25, 2024

Ownership

Company shareholders

NameShare classNumber of sharesShare
M
MP PENSJON PK
NO0010170855
3,372,250
34.58 %
I
INVESTOR CORPORATE AS
NO0010170855
1,958,862
20.09 %
NO0010170855
744,590
7.64 %
O
ORINOCO AS
NO0010170855
600,000
6.15 %
PJ
NO0010170855
515,833
5.29 %
NO0010170855
490,014
5.02 %
S
SEBEL INVEST AS
NO0010170855
224,000
2.3 %
P
PAR TRADING AS
NO0010170855
223,166
2.29 %
V
VENTUROS AS
NO0010170855
185,733
1.9 %
N
NORSEMETER AS
NO0010170855
120,000
1.23 %
NO0010170855
114,000
1.17 %
NO0010170855
110,000
1.13 %
A
AS MIMOSA
NO0010170855
101,605
1.04 %
NO0010170855
93,004
0.95 %
I
INTENTO AS
NO0010170855
90,000
0.92 %
NO0010170855
89,229
0.91 %
I
IVAR LØGE AS
NO0010170855
82,200
0.84 %
C
CREDIO AS
NO0010170855
75,000
0.77 %
NO0010170855
73,004
0.75 %
NO0010170855
61,000
0.63 %
NO0010170855
51,000
0.52 %
NO0010170855
47,200
0.48 %
NO0010170855
45,630
0.47 %
NO0010170855
40,000
0.41 %
C
CYGNUS VÅRSOL AS
NO0010170855
30,000
0.31 %
NO0010170855
23,304
0.24 %
NO0010170855
20,000
0.21 %
M
MOEMENTUM HOLDING AS
NO0010170855
17,195
0.18 %
N
NAVIO AS
NO0010170855
16,702
0.17 %
NO0010170855
16,450
0.17 %
A
A/S Skarv
NO0010170855
14,467
0.15 %
B
BJØRN AS
NO0010170855
12,342
0.13 %
A
ARIADNE INVEST AS
NO0010170855
12,342
0.13 %
H
HEINASKOGEN AS
NO0010170855
11,500
0.12 %
S
SESAM INVESTMENT AS
NO0010170855
8,225
0.08 %
N
NICOLAI SAMUELSEN AS
NO0010170855
8,225
0.08 %
W
WIECO AS
NO0010170855
7,925
0.08 %
G
GRANCO AS
NO0010170855
6,604
0.07 %
NO0010170855
6,500
0.07 %
S
SURFSIDE HOLDING AS
NO0010170855
5,086
0.05 %
F
FAGERBORG INVEST AS
NO0010170855
5,000
0.05 %
H
HOFINVEST AS
NO0010170855
4,116
0.04 %
E
EGD CAPITAL AS
NO0010170855
3,445
0.04 %
F
FAVN FORSIKRING
NO0010170855
2,125
0.02 %
T
TJUVHOLMEN INVEST AS
NO0010170855
2,000
0.02 %
NO0010170855
2,000
0.02 %
M
MUSTANG AS
NO0010170855
1,744
0.02 %
NO0010170855
1,328
< 0.01 %
H
HANTRI AS
NO0010170855
1,000
< 0.01 %
NO0010170855
532
< 0.01 %
NO0010170855
500
< 0.01 %
NO0010170855
278
< 0.01 %
T
TECHNOCULTURE OLIGO AS
NO0010170855
239
< 0.01 %
NO0010170855
100
< 0.01 %
Last update: May 24, 2024

Financials

in NOK

Summary

Year202320222021
Total operating income
5,709,789
5,586,949
2,944,250
Annual Total Result
5,554,028
-2,068,927
-2,174,925
Total assets
9,869,132
4,358,681
7,990,011
Total liabilities
6,284,198
6,327,775
7,890,178
Total equity
3,584,934
-1,969,094
99,832

P&L

Year202320222021
Total operating income
5,709,789
5,586,949
2,944,250
Total operating costs
-107,453
7,653,080
5,102,498
Operating result
5,817,241
-2,066,131
-2,158,248
Financial income/costs
-263,213
-2,796
-16,678
Profit before tax
5,554,028
-2,068,927
-2,174,925
Total tax & extraordinary income/cost
0
0
0
Annual Total Result
5,554,028
-2,068,927
-2,174,925

Balance overview

Year202320222021
Total fixed assets
7,080,201
1,062,824
1,299,007
Total current assets
2,788,931
3,295,857
6,691,004
Total assets
9,869,132
4,358,681
7,990,011
Short term debt
6,284,198
6,327,775
7,890,178
Long term debt
0
0
0
Total liabilities
6,284,198
6,327,775
7,890,178
Contributed capital
9,766,881
9,766,881
33,503,472
Retained earnings
-6,181,947
-11,735,975
-33,403,640
Total equity
3,584,934
-1,969,094
99,832
Total equity and liabilities
9,869,132
4,358,681
7,990,011

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology